The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.
For the Fifth Consecutive Year, NSH-BMT's One-Year Related and Unrelated Allogeneic Transplant Survival Outcomes Were Among the Best in the U.S.1,2
1. Reported outcome data from www.bethematch.com. This survival information includes only patients who received their first allogeneic transplant between January 1, 2009 and December 31, 2011 using unrelated or related donors, and who had reported follow-up. 2. Final 2013 Transplant Center Specific Survival Report, December 27, 2013.
Please go to Survival for additional NSH-BMT survival outcome data information.
NSH-BMT Sponsors April 26, 2014 Be The Match Walk-Run
On April 26, 2014, at Atlantic Station, Central Park, NSH-BMT Program’s Be The MatchWalk-Run Team raised over seven hundred dollars to help fight and cure blood cancers.(Place Run PDF flyer link here) This annual event brings the Atlanta community together to help provide cures for blood cancers.
NSH-BMT Collaborating with Dana-Farber Cancer Institute on Innovative Research Partnership
The Leukemia & Lymphoma Society (LLS) and the Dana-Farber Cancer Institute has established a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This groundbreaking Blood Cancer Research Partnership (BCRP), dana-farber.org/BCRP, will bring clinical trials closer to where patients live and help to address one of the primary bottlenecks in the development of new cancer therapies: the need for more patients to take part in trials. NSH-BMT is one of ten sites who have been selected to participate in this prestigious partnership.
LLS will be investing $1,050,000 in this three-year project. "This novel partnership between Dana-Farber Cancer Institute and LLS supports the mission of both organizations – to bring cutting-edge clinical research to a wider spectrum of patients with blood cancers today in order to change the paradigms of clinical care for patients tomorrow," said Blood Cancer Research Program Co-Director Robert Soiffer, M.D., who is the chief of the Division of Hematologic Malignancies at Dana-Farber. "The BCRP consortium will provide the opportunity for the Division of Hematologic Malignancies to extend clinical research trials to patients who are outside our regional area and do not have the capacity to come to Dana-Farber."
For more information about NSH-BMT’s collaboration with the Dana-Farber Cancer Institute, please call Stacey Brown, CCRP, Clinical Research & Data Supervisor, at 404-851-8238.
Atlanta Magazine Features NSH-BMT Program as Nominee for Groundbreaker of the Year for 2013
Atlanta Magazine has selected NSH-BMT as one of this year’s GroundBreaker of the year nominees. NSH-BMT Program and our patient, Bill Kahler, are featured in Atlanta Magazine’s November Groundbreaker edition. Bill underwent a haplo identical (half tissue match) allogeneic transplant where his son served as his donor. In collaboration with Johns Hopkins University’s Blood and Marrow Transplant Program, NSH-BMT has been a national leader in providing haploidentical transplants to those patients who do not have a full match related or unrelated allogeneic donor. NSH-BMT has organized their program to focus on factors that continuously produce outstanding survival outcomes; clinical research and quality.
2013 ASH Conference: NSH-BMT Recognized for Innovative Clinical Trial Results
The NSH - BMT Program has been selected to present at the 2013 American Society of Hematology (ASH) Meeting for their commitment to providing innovative clinical research trials to their blood and marrow transplant and leukemia patients. The presentations will include the following:
- Oral Presentation by Dr. Scott Solomon: Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT), Abstract #3337
- Five Posters by the NSH - BMT clinical pharmacists, Health Psychologist and BMT physician team members.
A Celebration of Life: NSH-BMT Hosts Survivor Reunion at The Fernbank Museum
On October 19, 2013, approximately five hundred guests, which included over 150 patients, their caregivers and the NSH-BMT Program staff came to the Fernbank Museum to celebrate their survivorship and life. Guests were inspired by the key note address given by our patient Alyssa Phillips. Alyssa spoke about her journey from being a patient to a survivor. Patients were recognized for their years into survivorship, including the very first patient transplanted at NSH-BMT over 15 years ago. Ray Stovall and Martha Stovall, Stovall Hope Foundation, were honored with an award recognizing their years of service to NSH-BMT patients and families. The Stovall Hope Foundation allows patients and their caregivers to stay in comfortable, spacious and cost-free living quarters while undergoing transplant services at NSH-BMT.
Our special thanks to Dr. Gerry Connaghan, who travelled from Dublin Ireland to attend this special event. Dr. Connaghan was a founding physician of The Blood and Marrow Transplant Group of Georgia.
NSH-BMT/Leukemia’s Health Psychologist Dawn Speckhart, PH.D. to Present at 2013 11th Annual American Psychosocial Oncology Association Meeting.
NSH-BMT/Leukemia's health psychologist, Dawn Speckhart,Ph.D., in collaboration with colleagues from the University of Colorado, Denver and the Colorado Blood Cancer Institute, Presbyterian/St.Luke’s Medical Center, will present an oral presentation, ‘Disease Comorbidity Predicts Length of Hospitalization Whereas Psychosocial Risk Predicts Patient Survival One Year Post Hematopoietic Stem Cell Transplantation’, Abstract # 0250, and NSH-Leukemia program poster presentation, ‘Implementation of a Systematic Approach to Increase Occurrence and Documentation of Fertility Discussions in Newly Diagnosed Acute Leukemia Patients Prior to Induction Chemotherapy’. The NSH-BMT/Leukemia program congratulates Dr. Speckhart on her national recognition and her contributions to advance the field of health psychology in blood and marrow transplant and leukemia treatment.
NSH- BMT featured on National Broadcast with Larry King
NSH-BMT was selected by In View productions to be featured in a national broadcast showcasing innovative medicine. The show is hosted by Larry King and was aired for national viewing on the Discovery Channel on May 15 at 7:00 AM EST. Please visit the links below to view the productions.
To view a more in depth video of the NSH-BMT program, click here
NSH-BMT Program is Now Enrolling to the Following Innovative Clinical Trial
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals: NSH IRB 959
Phase II BMT CTN multi-center trial to assess the feasibility and safety of reduced-intensity or fully-ablative allogeneic hematopoietic cell transplantation (HCT) in HIV-infected patients. 15 patients will be transplanted at multiple sites over two years. Where feasible, an attempt will be made to identify HLA-compatible hematopoietic stem cell donors who are homozygotes for the delta32 mutation of the chemokine receptor 5 (CCR5delta32). Patients will undergo a treatment plan review prior to registration on the trial. All patients will undergo allogeneic HCT from a matched sibling or unrelated donor. The physician will choose the regimen. This study is sponsored by NIH & BMT CTN. For additional study information and inclusion/exclusion criteria, please click here.
For more information, please call Stacey Brown, CCRP, Clinical Research & Data Supervisor at 404-851-8238.
NSH-Leukemia Program is Now Enrolling to the Following Innovative Clinical Trials
An Open-Label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22+ Acute Lymphoblastic Leukemia (ALL): NSH IRB 1011
An open label, mutli-center randomized (1:1) phase III study in patients with relapsed or refractory CD22+ ALL to determine the efficacy (defined as CR/CRi) of inotuzumab ozogamicin (Arm A) versus the investigator’s choice of chemotherapy (Arm B). At least 194 patients are expected to be randomized overall over approximately 26 months. The trial is sponsored by Pfizer and inotuzumab ozogamicin will be provided to the site. For additional study information and inclusion/exclusion criteria, please click here.
Phase III Randomized Clinical Trial of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: NSH 923
Phase III Randomized Trial of oral Sapacitabine/Decitabine vs. Decitabine only in elderly patients with newly diagnosed acute myeloid leukemia (AML).For additional study information and inclusion/exclusion criteria, please click here.
For more information, please call Stacey Brown, CCRP, Clinical Research & Data Supervisor at 404-851-8238.
National Marrow Donor Program (NMDP): Post Transplant Mobile App is Now Available
To help physicians with the reference materials they need to care for transplant patients, the NMDP has developed an app with leading transplant organizations to help increase survival rates. For more information, please go to Post BMT Discharge Instructions.
NSH-BMT Patient Asa Valente Meets Her Unrelated Donor at the
2012 BeTheMatch Tribute Dinner
On September 22, 2012, Asa Valente, a NSH-BMT patient who received primary leukemia treatment and an unrelated donor transplant in 2011, met her British donor, Edward Collier, at the 2012 BeTheMatch Tribute Dinner. Edward is a medical student who became involved in blood/marrow donor donation through a donor drive held at his medical school, Imperial College in London, England. Through his selfless generosity, Edward has given Asa a gift of a healthy and bright future.
Please click here to read more of Asa’s story,by Michelle Hiskey, or visit at Saportareport.com.
NSH-BMT Program Named as Core Clinical Transplant Center
NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.
Join the Fight Against Cancer
By donating platelets and blood you can join the fight and directly impact the healthcare of patients being treated at NSH-BMT/Leukemia by donating with Atlanta Blood Services. To donate or find out additional information please go to http://www.atlantabloodservices.com/index.htm Or Click here to Like ABS on Facebook: http://www.facebook.com/atlantabloodservices
The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.